Researcher in lab

Find clinical trials

Our clinical trial portfolio is one of the largest in the country. We have more than 700 clinical trials open across 30 clinical units.

Clear filter
599 clinical trials found
Clinical trials

Velora Discover - HMB-002-101_SCR

A Prospective, Screening Study of Bleeding and Treatment in Participants with Von Willebrand Disease

This is a non-interventional observational study in participants with confirmed Type 1 VWD according to diagnostic guidelines. The study includes screening, a baseline evaluation, and an approximately 4-month observation period which will include every other week telemedicine check-ins (to monitor bleed diary entries and bleeding event treatments.?
Currently recruiting

VISOR

Virtual Reality Integrated Social Recovery therapy for Young People with Early Psychosis (ACTRN12624000234516)

This study aims to test the effectiveness of a new and improved version (version 2) of a virtual reality intervention designed to support the social and cognitive recovery of young people with early psychosis. The study will compare version 2 with the previous version 1, to determine if the new version is more effective in improving social functioning.
Currently recruiting

VM-002-101

A first-in-human, phase 1, multi-center, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary evidence of antitumor activity of IDOV-Immune in adult participants with advanced solid tumors (NCT06910657)

This is a Phase I clinical trial evaluating an investigational treatment called IDOVImmune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments. Oncolytic viruses are designed to infect and destroy cancer cells and have the potential to stimulate the immune system to fight the tumor. The purpose of this study is to determine the safety of IDOV-Immune, how well it is tolerated, and to identify the highest dose that can be safely given. Researchers will also study how the drug behaves in the body, how the immune system responds to it, and whether it shows any signs of shrinking tumors. Participants will receive a single intravenous (IV) infusion of IDOV-Immune and will be closely monitored for side effects and any changes in their cancer. This study is being conducted at multiple sites in the United States and Australia.
Currently recruiting

Xenon 304

A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of XEN1101 in Adults Diagnosed With Epilepsy

A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of XEN1101 in Subjects Diagnosed With Epilepsy
Currently recruiting

YKP509C003

YKP509C003 Protocol: A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Carisbamate [YKP509] as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults, With Optional Open-Label Extension

The primary objective is to evaluate the efficacy of carisbamate (YKP509) as adjunctive treatment in reducing the number of drop seizures (tonic, atonic, and tonic-clonic) compared with placebo in pediatric and adult subjects (age 4-55 years) diagnosed with Lennox Gastaut Syndrome (LGS).
Currently recruiting